Clinical Trials
97 trialsDESCENT-1
A2 Biotherapeutics Inc.
MACRONAC
University Hospital, Basel, Switzerland
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
Emory University
PRIME-TNBC
Center Eugene Marquis
ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC
University of Pittsburgh
BASECAMP-1
A2 Biotherapeutics Inc.
CAPTIVATE
Barts & The London NHS Trust
Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
Fudan University
BELIEVE
Royal Marsden NHS Foundation Trust
FERTILE
Peter MacCallum Cancer Centre, Australia
Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC
The First Affiliated Hospital with Nanjing Medical University
Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer
Hackensack Meridian Health
AIDOBE
Institute of Cancer Research, United Kingdom
PERCEPTION
Centre Jean Perrin
TRIPLEX
Centre Francois Baclesse
MIMIR-mTNBC
Karolinska University Hospital
FORTITUDE
Royal Marsden NHS Foundation Trust
MINA
University College Cork
GEMINI Breast
Tempus AI
Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
Daiichi Sankyo
PDO-Mercurial
Istituti Clinici Scientifici Maugeri SpA
Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer
University Hospital Tuebingen
ELEPHAS-05
Elephas
ENCORE
University of California, San Francisco
INSTIGO
Centre Jean Perrin
PDO-Neo01
Istituti Clinici Scientifici Maugeri SpA
NEUTROFLOW
OncoHost Ltd.
Axillary Nodal Burden in HER2+ and TNBC
Gangnam Severance Hospital
PROGECT
University of Kansas Medical Center
BRAVA
Gene Solutions
Comparison of the Breast Tumor Microenvironment
Columbia University
PEAR-TNBC
Ourotech, Inc.
Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
Hunan Cancer Hospital
Role of the Immune Environment in Response to Therapy in Breast Cancer
Abramson Cancer Center at Penn Medicine
START
Lyell Immunopharma, Inc.
Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
Peking University Cancer Hospital & Institute
Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration
Peking University Cancer Hospital & Institute
TIL; PD1; PDL1
Ziauddin University
OPTImaL
The Netherlands Cancer Institute
A Multicenter Cancer Biospecimen Collection Study
Cofactor Genomics, Inc.
Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer
Fudan University
B-STRONGER-I
Personalis Inc.
Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
Masonic Cancer Center, University of Minnesota
NeoTNBCX
Peking University People's Hospital
Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment
Vanderbilt-Ingram Cancer Center
NacTNBC
Peking University People's Hospital
Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies
Institute of Applied Biosciences
A-TRAIN
National Cancer Center, Japan